Nebivolol and S-Amlodipine Tablets
- Nebivolol 5 mg & S-Amlodipine 5 mg Tablets
Therapeutic Class: Cardiovascular Agents
Dosage Forms: Tablets
Brand Name: BEVOS™
How it works?
Uses of Nebivolol and S-Amlodipine Tablets
- Essential hypertension → Helps lower high blood pressure, reducing the risk of stroke, heart attack, and kidney complications.
- Chronic stable angina → Relieves chest pain and discomfort by improving blood flow to the heart.
- Nebivolol action → A beta‑blocker that reduces heart rate, decreases oxygen demand, and improves cardiac efficiency.
- S‑Amlodipine action → A calcium channel blocker that relaxes and widens blood vessels, lowering vascular resistance.
- Dual benefit → Controls blood pressure and alleviates angina simultaneously, reducing strain on the heart.
- Improved circulation → Enhances overall blood flow, prevents complications, and supports better heart function.
- Quality of life → Provides long‑term cardiovascular protection and symptom relief, improving daily living for patients.
Precautions of Nebivolol and S-Amlodipine Tablets
Nebivolol:
Anesthesia: Continuation of beta-blockade reduces the risk of arrhythmias during induction and intubation. Exercise caution with certain anesthetics that cause myocardial depression.
Avoid using beta-adrenergic antagonists in patients with untreated congestive heart failure (CHF). Gradually discontinue beta-adrenergic antagonists in patients with ischemic heart disease. Avoid combining nebivolol with calcium channel antagonists like verapamil and diltiazem.
Metabolic/Endocrinological: does not affect glucose levels in diabetic patients.
Use beta-adrenergic antagonists with caution in patients with chronic obstructive pulmonary disorders, as they may aggravate airway constriction.
Amlodipine:
Researchers have not established the safety and efficacy of amlodipine in hypertensive crises.
Treat patients with heart failure with caution, as they may experience complications. Use calcium channel blockers, including amlodipine, cautiously in patients with congestive heart failure.
In patients with hepatic impairment, the prolonged half-life of amlodipine and higher AUC values occur, but clinicians have not established dosage recommendations.
Elderly patients: In the elderly, an increase of the dosage should take place with.
Patients with renal impairment can use amlodipine at normal doses, as changes in amlodipine plasma concentrations do not correlate with the degree of renal impairment.
Dosages administration of Nebivolol and S-Amlodipine Tablets
- Adults → Usual dose: 1 tablet (5mg/5mg) once daily, with or without food. Maximum dose: 5mg/10mg once daily.
- Elderly → Recommended starting dose: 1 tablet (2.5mg/5mg) daily. May increase to 5mg/10mg if needed.
- Renal impairment → Mild to moderate: no adjustment required. Severe (ClCr < 30 mL/min): start with 2.5mg/5mg once daily, titrate cautiously if needed.
- Hepatic impairment → Moderate (Child‑Pugh B): start with 2.5mg/5mg once daily, titrate cautiously. Severe: not recommended.
- Children & adolescents → Not studied; use is not recommended.
- CYP2D6 polymorphism → No dose adjustment required; poor metabolizers show similar safety and efficacy to extensive metabolizers.
Side effects of Nebivolol and S-Amlodipine Tablets
Nebivolol:
Hypertension
The adverse reactions reported, which are in most of the cases of mild to moderate intensity, are listed below, classified by system organ class and ordered by frequency:
Common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), very rare (≤ 1/10,000) and not known adverse reactions occurring in patients treated with nebivolol are listed below.
Immune system disorders
Not known: angioneurotic oedema, hypersensitivity
Psychiatric disorders
Uncommon: nightmares, depression
Nervous system disorders
Common: headache, dizziness, paresthesia; Very rare: syncope
Eye disorders
Uncommon: impaired vision
Cardiac disorders
Uncommon: bradycardia, heart failure, slowed AV conduction/AVblock
Vascular disorders
Uncommon: hypotension, (increase of) intermittent claudication
Respiratory, thoracic and mediastinal disorders
Common: dyspnoea; Uncommon: bronchospasm
Gastro-intestinal disorders
Common: constipation, nausea, diarrhoea; Uncommon: dyspepsia, flatulence, vomiting
Chronic heart failure
Data on adverse reactions in CHF patients are available from one placebo-controlled clinical trial involving 1067 patients taking nebivolol and 1061 patients taking placebo. In this study, a total of 449 nebivolol patients (42.1%) reported at least possibly causally related adverse reactions compared to 334 placebo patients (31.5%). The most commonly reported adverse reactions in nebivolol patients were bradycardia and dizziness, both occurring in approximately 11% of patients. The corresponding frequencies among placebo patients were approximately 2% and 7%, respectively.
Amlodipine:
The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.
The following adverse reactions have been observed and reported during treatment with amlodipine with the following frequencies: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Blood and lymphatic system Disorders
Very rare: Leukocytopenia, thrombocytopenia
Immune system disorders
Very rare: Allergic reactions
Metabolism and nutrition Disorders
Very rare: Hyperglycemia
Psychiatric disorders
Uncommon: Depression, mood changes (including anxiety), insomnia; Rare: Confusion
Nervous system disorders
Common: Somnolence, dizziness, headache; Uncommon: Tremor, dysgeusia; Very rare: Hypertonia
Cardiac disorders
Common: Palpitations; Uncommon: Arrhythmia
Respiratory, thoracic and mediastinal disorders
Common: Dyspnoea; Uncommon: Cough, rhinitis
Gastro-intestinal disorders
Common: Abdominal pain, nausea, dyspepsia, altered bowel habits; Uncommon: Vomiting, dry mouth
Renal and urinary disorders
Uncommon: Micturition disorder, nocturia, increased urinary frequency
Reproductive system and breast disorders
Uncommon: Impotence, gynaecomastia
Storage instruction of Nebivolol and S-Amlodipine Tablets
Store below 30°C. Protect from light and moisture.
Keep out of reach of children.
Packing details of Nebivolol and S-Amlodipine Tablets
3 x 10 Alu/Alu blister pack
BEVOS is available in an Alu/Alu blister of 10 tablets. Such 03 blisters in a unit carton with package insert.
interested? let’s talk.
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Reliable GMP Certified Nebivolol and S-Amlodipine Tablets Manufacturer
Conical Pharmaceuticals, headquartered in Ahmedabad, India, is a GMP‑certified manufacturer & exporter of Nebivolol + S‑Amlodipine Tablets, delivering premium pharmaceutical and nutraceutical solutions worldwide.
Belonging to the antihypertensive therapeutic class, this fixed‑dose combination is indicated for the treatment of essential hypertension and chronic stable angina. Nebivolol, a beta‑blocker, reduces heart rate and oxygen demand, while S‑Amlodipine, a calcium channel blocker, relaxes and widens blood vessels. Together, they improve circulation, reduce strain on the heart, and enhance patient quality of life.
With exports planned into Central Africa, Central America, and the CIS Region, and expanding into Nigeria, Ghana, Zambia, Zimbabwe, Kenya, the Philippines, Singapore, and Afghanistan, Conical Pharmaceuticals ensures reliable supply and smooth market entry. Importers benefit from complete regulatory dossier support, including GMP Certification, COPP, COA, and Free Sale Certificates.
We also provide third‑party contract manufacturing, bulk supply of pharmaceutical tablets, private labelling, and custom formulation options, empowering partners to launch their own brands with tailored solutions. With advanced R&D, flexible MOQ options, and consistent quality assurance, Conical Pharmaceuticals enables partners to expand their market presence while delivering effective, high‑quality cardiovascular therapies worldwide.
CUSTOM PACKAGING
Options available in size and style to meet your exact specifications and branding needs
SAMPLES AVAILABLE
Test before committing to bulk orders with complimentary samples for quality verification
LEAD TIME
45–60 days for timely delivery, ensuring reliable supply chain management
SHELF LIFE
Shelf Life: 24 months.
Frequently Asked Questions
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
-
Conical Pharmaceuticals, headquartered in Ahmedabad, India, is a GMP‑certified manufacturer & exporter of this dual‑therapy.
-
-
-
-
-
